ALLR — Q2 2026 Financial Report Analysis

Allarity Therapeutics, a clinical-stage cancer-drug developer with no product sales, narrowed its spending in the second quarter of 2026 but reported a wider net loss of $3.4 million, up from $2.3 million a year earlier. Operating costs fell 35% as the bulk of 2025's trial and supply spending rolled off, but two non-operating items moved against it: a $1.6 million currency gain that flattered last year's quarter did not repeat, and $0.7 million of interest started flowing from the $20 million of debt it took on in March. The financial story of the half-year is that loan: it lifted cash and restricted cash to $26.9 million, but it put $20.9 million of current debt on a balance sheet that now carries only $3.5 million of shareholders' equity.

At a glance

• $17.0 million of freely usable cash at June 30 (plus $10.0 million locked up as collateral for one of the loans). At the first half's operating cash burn of $7.1 million, that covers roughly 14 months of spending before repaying anything on the unsecured loan.
• Operating expenses of $2.7 million, down 35% from $4.1 million. Research spending fell 42% because the costs of supplies for the Phase 2 trial of its lead drug, stenoparib, were largely booked in 2025.
• No going-concern warning. Management's formal assessment concludes cash will cover at least the next twelve months, so the auditor-style "substantial doubt" language that often accompanies micro-cap biotechs is absent from this filing.

The quarter in numbers

The only revenue in the first half was $25,000 in the first quarter from licensing its DRP testing services; there was none in either second quarter, so operating margin isn't a meaningful figure here.

Takeaway: The March loan solved this year's funding but not next year's. Both Streeterville notes mature on September 2, 2027 — less than three weeks after the twelve-month window management's "enough cash" statement covers. The secured $10 million note is backed by its own restricted cash, but the unsecured note (about $10.9 million face value plus a $2.0 million monitoring fee and 9% interest) has to come out of the $17.0 million of free cash that is also funding the stenoparib program, so at the first half's burn rate Allarity will need new money — most likely share sales — before that maturity.

What drove the results

Spending fell for specific reasons. The filing attributes the $1.0 million drop in research and development to "reduced costs and supplies of the Phase II clinical trial of stenoparib," noting that a significant amount of those costs were recognized in 2025 at the time of purchase. General and administrative costs fell $0.5 million "primarily due to a reduction in legal fees." Neither is a sign of the trial winding down: management says it expects research costs on stenoparib "to increase substantially" as it prepares a registrational (approval-enabling) trial.

The net loss widened anyway, for non-operating reasons. Loss from operations improved by $1.5 million, but "other income" swung by $2.5 million in the wrong direction:

• Last year's quarter had a $1.6 million foreign-exchange gain (Allarity's main operations are in Denmark, so swings between the Danish krone and the dollar run through this line). This year it was a $0.1 million loss.
• Interest expense rose to $0.7 million from $12,000, and the company booked a $0.1 million charge for remeasuring the stock-price-linked features embedded in one of the notes. Both stem from the March 2026 Streeterville financing.

Strip out the currency line and the loss actually shrank: about $3.3 million this quarter versus about $3.9 million a year ago.

The March financing: what Allarity actually owes

On March 2, 2026 Allarity sold two promissory notes to Streeterville Capital for $20.0 million of gross proceeds:

Three terms matter for shareholders:

• The monitoring fee raises the cost sharply. Ninety days after issuance the A-1 balance was grossed up by about 18% (balance ÷ 0.85, minus the balance), adding $1.97 million that itself accrues interest. The fee is forgiven pro rata each time Allarity makes a cash payment, which pushes the company toward repaying in cash rather than letting the balance run.
• Redemptions start now. From six months after issuance (early September 2026), Streeterville can demand cash redemptions of up to $250,000 a month across both notes, plus extra early redemptions if the share price hits specified levels. Redemptions on the B Note release matching restricted cash, so they are largely neutral; redemptions on the A-1 Note draw down free cash.
• The B Note is mostly a round trip. Its $10 million sits in a controlled account and is released only as the note is repaid. Economically, the $26.9 million cash headline overstates usable liquidity by that $10 million.

The company also signed an equity line with Tumim Stone Capital in January: the right, not the obligation, to sell up to $6.0 million of new shares at a 3–5% discount to recent trading prices. It sold just 2,000 shares ($2,000) under it in the half, leaving about $6.0 million available.

What the headline numbers hide

• Cash conversion: operating cash burn ($7.1 million for the half) was larger than the net loss ($6.2 million). The main reason is a $1.3 million rise in prepaid expenses: per the earnings release, Allarity paid in full during the quarter for a stenoparib manufacturing campaign completed in July, and expects no further cash outlay for that drug supply. That makes the second-half burn likely to be lower, but it also means the $3.4 million prepaid balance is drug supply already paid for, not cash.
• Non-cash interest: $0.9 million of the half's interest expense was non-cash (discount amortization and accrued interest added to the balance). It doesn't consume cash now, but it adds to what is owed at maturity.
• Book equity collapsed: shareholders' equity fell to $3.5 million from $9.8 million at year-end, because the net loss was funded with debt rather than share sales. Total liabilities ($28.6 million) are now all current.
• An old liability still sits on the books: about $5.6 million owed to Novartis from a drug license Novartis terminated in January 2024 ($3.6 million in accounts payable, $1.4 million of convertible notes and interest, $0.6 million accrued), all classified as current and accruing 5% interest.
• Buybacks alongside borrowing: Allarity spent $0.26 million repurchasing 264,000 shares in the first quarter (none in the second) while borrowing at 9% plus fees; $4.9 million of authorization remains. Small, but an unusual use of cash for a company that will need to raise capital again.
• Dilution so far is limited: weighted shares rose only 2.4% year over year to 15.9 million, and shares outstanding fell slightly from year-end because of the buybacks. Note the per-share loss comparison is distorted less by share count than by last year's currency gain.
• The derivative line is small but stock-sensitive: the embedded features in the A-1 Note were valued at a net $0.13 million liability using a 91% volatility assumption; it will swing with the share price each quarter.

Outlook

Management gives no financial guidance. What it does say: it expects research spending to "increase substantially" as stenoparib moves toward a pivotal trial, following FDA Fast Track designation in ovarian cancer and Phase 2 data presented at AACR 2026 linking higher DRP scores (its gene-expression test meant to pick out patients likely to respond) to longer survival. During the quarter it received a U.S. patent covering stenoparib used with its DRP test into April 2042; in July it completed the drug-supply manufacturing campaign for late-stage trials and obtained CLIA certification (the U.S. lab-quality standard) for its Danish lab, so it can run the DRP test in-house.

Our read: the science milestones in the release are real progress for a company this size, but a registrational trial costs far more than the $2.7 million a quarter Allarity is spending now. With roughly $17 million of free cash, a 2027 debt wall, and the filing itself warning that funding through share sales "could be highly dilutive," the most likely path is new equity — through the Tumim line or a larger offering — well before the notes mature. The things to watch next quarter are whether Streeterville begins monthly redemptions from September, whether any shares are issued under the Tumim line, and whether R&D spending starts climbing as the pivotal trial is set up.